Protection of macaques against infection with simian type D retrovirus (SRV-1) by immunization with recombinant vaccinia virus expressing the envelope glycoproteins of either SRV-1 or Mason-Pfizer monkey virus (SRV-3)

J Virol. 1992 Jun;66(6):3950-4. doi: 10.1128/JVI.66.6.3950-3954.1992.

Abstract

Rhesus macaques were immunized with live vaccinia virus recombinants expressing the envelope glycoproteins (gp70 and gp22) of simian type D retrovirus (SRV), serotype 1 or 3. All of the animals immunized with either the SRV-1 env or the SRV-3 env vaccinia virus recombinant developed neutralizing antibodies against the homologous SRV. In addition, both groups developed cross-reactive antibodies and were protected against an intravenous live-virus challenge with SRV-1. The four control animals immunized with a vaccinia virus recombinant expressing the G protein of respiratory syncytial virus were not protected against the same SRV-1 challenge. Although SRV-1 and SRV-3 immune sera showed cross-neutralization, they failed to neutralize a separate, more distantly related serotype, SRV-2, in an in vitro assay. These findings are consistent with the known degree of serologic and genetic relatedness of these three SRV strains.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibody Formation
  • Antigens, Viral / immunology
  • Glycoproteins / immunology
  • HN Protein*
  • Immunotherapy, Active*
  • Macaca
  • Respiratory Syncytial Viruses / immunology
  • Retroviruses, Simian / immunology*
  • Simian Acquired Immunodeficiency Syndrome / therapy*
  • Specific Pathogen-Free Organisms
  • Vaccines, Synthetic / therapeutic use*
  • Vaccinia virus / genetics
  • Viral Envelope Proteins / immunology
  • Viral Proteins*

Substances

  • Antigens, Viral
  • Glycoproteins
  • HN Protein
  • Vaccines, Synthetic
  • Viral Envelope Proteins
  • Viral Proteins
  • attachment protein G